Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Institut Gustave Roussy.   Recruitment status was  Recruiting

First Received on September 13, 2005.  
Last Updated on September 24, 2007  
History of Changes
Sponsor: Institut Gustave Roussy
Information provided by: Institut Gustave Roussy Identifier: NCT00180921

This is a Phase II study of imatinib (Glivec) administered as a daily oral treatment in patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT.

Condition Intervention Phase
Cancer of the Head and Neck
Carcinoma, Adenoid Cystic
Drug: Imatinib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT

Resource links provided by NLM:

Further study details as provided by Institut Gustave Roussy:

Primary Outcome Measures:

  • To assess progression-free survival under treatment with imatinib mesylate in patients with relapsing/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT. [ Time Frame: at 6 months ]

Secondary Outcome Measures:

  • The secondary objectives are to estimate the objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria), disease control and overall survival.

Estimated Enrollment: 30
Study Start Date: July 2004

Detailed Description:

Patients with relapsing and/or metastatic adenoid cystic carcinoma of the salivary gland of the head and neck are usually poor responders to conventional cytotoxic chemotherapy.

The investigation of proliferation pathways involving tyrosine kinase receptors such as c-kit receptor (KIT) and PDGF receptor may allow to identify a molecular target for novel therapeutic approaches in patients with adenoid cystic carcinoma who failed locoregional treatment.

Several publications in the literature and the pathological study we conducted in Institut Gustave Roussy show that KIT overexpression is observed in at least 80-90% of the cases of adenoid cystic carcinoma, supporting the investigation of imatinib in patients with adenoid cystic carcinoma overexpressing KIT.

Imatinib is an orally administrated, well tolerated compound that could be given on an outpatient schedule to patients with relapsing/metastatic adenoid cystic carcinoma of the head and neck.

Because of the infrequent occurrence of salivary gland malignancies, a multicenter trial will be mandatory and the study will include at least 2 centers represented by Institut Gustave Roussy, Villejuif; and Hôpital Georges-Pompidou, Paris.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven adenoid cystic carcinoma overexpressing KIT (by immunohistochemistry) with recurrent disease documented by computed tomography (CT) scan or magnetic resonance imaging (MRI).
  • Presence of at least one dimensionally measurable target lesion (contrast enhancing lesion with the largest diameter >= 2 cm, based on CT or MRI scan done within 4 weeks before the start of treatment).
  • Patients able to swallow an oral compound.
  • World Health Organization (WHO) performance status < 2.
  • Life expectancy of >= 3 months.
  • Aged >= 18 years.
  • Normal hematological (neutrophils >= 1.5 x 10^9 cells/l, platelets >= 100 x 10^9 cells/l), hepatic (bilirubin < 1.5 times the upper limit of the normal range; alkaline phosphatase and transaminases <= 2.5 x the upper limit of the normal range) and renal (serum creatinine <= 150 mmol/l) functions.
  • Written informed consent.

Exclusion Criteria:

  • Abnormal cardiac function with history of ischaemic heart disease in the past 6 months and/or abnormal 12 lead electrocardiogram (ECG).
  • Previous or current malignancies at other sites with the exception of cone biopsied carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma.
  • Concomitant treatment with warfarin or any other anticoagulants.
  • Unstable systemic diseases or active uncontrolled infections.
  • Patients (male and female) not using effective contraception if of reproductive potential.
  • Females pregnant or lactating or positive beta human chorionic gonadotropin (bHCG) at baseline
  Contacts and Locations

Please refer to this study by its identifier: NCT00180921

Contact: Sandrine Faivre, MD 33 1 40 87 50 25

Institut Gustave Roussy Recruiting
Villejuif, France, 94800
Contact: Sandrine Faivre, MD     33 1 40 87 50 25    
Contact: Caroline Robert, MD     33 1 42 11 42 53    
Sponsors and Collaborators
Institut Gustave Roussy
Principal Investigator: Sandrine Faivre, MD Centre Hospitalier de Beaujon
  More Information

No publications provided Identifier: NCT00180921    
History of Changes
Other Study ID Numbers: CSTI BFR 17
Study First Received: September 13, 2005
Last Updated: September 24, 2007
Health Authority: France: Afssaps – Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Institut Gustave Roussy:

Adenoid cystic carcinoma of the head and neck

Additional relevant MeSH terms:

Carcinoma, Adenoid Cystic
Head and Neck Neoplasms
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Squamous Cell
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




3 × 2 =